Skip to main content

Peer Review reports

From: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Original Submission
24 Apr 2023 Submitted Original manuscript
18 Sep 2023 Reviewed Reviewer Report
28 Sep 2023 Reviewed Reviewer Report - Guenther G. Steger
10 Oct 2023 Reviewed Reviewer Report
14 Nov 2023 Author responded Author comments - Chuangui Song
Resubmission - Version 2
14 Nov 2023 Submitted Manuscript version 2
23 Nov 2023 Author responded Author comments - Chuangui Song
Resubmission - Version 3
23 Nov 2023 Submitted Manuscript version 3
29 Nov 2023 Reviewed Reviewer Report
29 Nov 2023 Reviewed Reviewer Report
5 Dec 2023 Reviewed Reviewer Report - Guenther G. Steger
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
5 Dec 2023 Editorially accepted
2 Jan 2024 Article published 10.1186/s12885-023-11722-4

You can find further information about peer review here.

Back to article page